Calquence logo, drug

AstraZeneca Begins Clinical Trial of Calquence as COVID-19 Treatment

April 15, 2020

AstraZeneca is conducting a phase 2 trial of its BTK inhibitor Calquence (acalabrutinib) for treatment of exaggerated immune response in COVID-19 patients.

The CALAVI trial will evaluate the safety and efficacy of adding Calquence to best supportive care to reduce mortality and the need for assisted ventilation.

Calquence is currently approved for treatment of chronic lymphocytic leukemia and mantle cell lymphoma in adults who have received at least one prior therapy.

View today's stories